Private Equity
New York City-based Rgenix, Inc, a developer of small molecule and antibody cancer therapeutics, has named Dr. Peter Van Vlasselaer to its board of directors. Recently, he was the president and CEO of ARMO Biosciences. Rgenix's backers include Novo A/S, Sofinnova Partners, Lepu Medical, Oceanpine Capital, WuXi AppTec’s Corporate Venture Fund, Alexandria Venture Investments and the Partnership Fund for New York City’s Innovate NY Fund.
3 min read · 27 November 2018
Frazier Healthcare Partners has named Dr. Mimi Hancock to its life sciences team as a senior adviser. Previously, she was a member of Spencer Stuart's life sciences practice.
2 min read · 27 November 2018
Brooklyn, New York-based Quip, an oral health company, has secured $40 million in funding. The lead investor was Sherpa Capital.
1 min read · 27 November 2018
4 min read · 27 November 2018
Palo Alto, California-based Technology Impact Growth Fund is raising $200 million, according to a regulatory filing. Listed as the fund's managers are Dipender Saluja and Ion Yadigaroglu. The two are partners at the Capricorn Investment Group, an investment firm formed by former eBay President Jeffrey Skoll.
1 min read · 27 November 2018
2 min read · 26 November 2018
Enterprise-focused, early-stage investor Storm Ventures is seeking to raise a sixth fund, according to a regulatory filing. The filing did not disclose a target amount. The firm’s current fifth fund closed at its hard cap of $180 million in 2015. Earlier this year, Storm Ventures added Paul Willard as a partner and has promoted Arun Penmetsa to partner, joining Managing Directors Ryan Floyd and Tae Hea Nahm.
1 min read · 26 November 2018
Wildcat Venture Partners has set out to raise a $120 million second venture-capital fund, according to a filing with the SEC.
1 min read · 26 November 2018
SignalFire has set out to raise a third venture-capital fund, according to a filing with the SEC. No target or first close was listed.
1 min read · 26 November 2018
Coatue Management has set out to raise an early-stage venture-capital fund, according to a filing with the SEC. No fund target or first close was listed.
1 min read · 26 November 2018